Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces additional data on safety, quality of life and survival from POSEIDON, its North American pivotal study of alfapump for the treatment of patients with recurrent or refractory ascites due to liver cirrhosis. These data will be presented during a poster session today and have been selected for an oral poster presentation on June 23rd from 12:45 to 12:55 CEST at the EASL Congress in Vienna, Austria.

Professor Florence Wong, University of Toronto, Hepatologist at Toronto General Hospital, Ontario, Canada and Principal Investigator for the POSEIDON study, commented: “Recurrent or refractory ascites has a negative impact on patients’ lives requiring management with regular paracentesis. The results from the POSEIDON study have shown that the alfapump is very effective at controlling this, virtually eliminating the need for large volume paracentesis and significantly improving patients’ quality of life at six months post-implantation. While patients implanted with the alfapump need to be closely monitored for the development of acute kidney injury or infection, in the POSEIDON study these events readily resolved with the standard of care.”

Ian Crosbie, Chief Executive Officer at Sequana Medical, added: “We are excited about this further POSEIDON data as we believe it continues to support alfapump as a breakthrough for recurrent or refractory liver ascites patients. Together with the positive primary endpoint data reported previously, these results further support the clinical benefits of the alfapump and show a survival rate that compares favorably to literature. With more than 75,000 people in North America suffering from recurrent or refractory liver ascites by 2025, and growing by 6-7% a year due to NASH, modern and effective solutions like alfapump are urgently needed.”

Download full article